AU2020221796A1 - Crystalline forms of a JAK2 inhibitor - Google Patents

Crystalline forms of a JAK2 inhibitor Download PDF

Info

Publication number
AU2020221796A1
AU2020221796A1 AU2020221796A AU2020221796A AU2020221796A1 AU 2020221796 A1 AU2020221796 A1 AU 2020221796A1 AU 2020221796 A AU2020221796 A AU 2020221796A AU 2020221796 A AU2020221796 A AU 2020221796A AU 2020221796 A1 AU2020221796 A1 AU 2020221796A1
Authority
AU
Australia
Prior art keywords
crystalline
crystalline form
compound
sample
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020221796A
Other languages
English (en)
Inventor
Pascal Billot
Benoit Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of AU2020221796A1 publication Critical patent/AU2020221796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020221796A 2019-02-12 2020-02-11 Crystalline forms of a JAK2 inhibitor Abandoned AU2020221796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR1902018 2019-02-12
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
AU2020221796A1 true AU2020221796A1 (en) 2021-08-12

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020221796A Abandoned AU2020221796A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a JAK2 inhibitor

Country Status (13)

Country Link
US (1) US20220332706A1 (https=)
EP (1) EP3927704A4 (https=)
JP (2) JP2022520083A (https=)
KR (1) KR20210148110A (https=)
CN (1) CN114026088A (https=)
AU (1) AU2020221796A1 (https=)
BR (1) BR112021015318A2 (https=)
EA (1) EA202192237A1 (https=)
FR (1) FR3092581A1 (https=)
IL (1) IL285427A (https=)
MX (1) MX2021009423A (https=)
SG (1) SG11202108607QA (https=)
WO (1) WO2020167844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) * 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
TW201316989A (zh) * 2011-07-21 2013-05-01 Sanofi Sa 用於治療真性多血症及原發性血小板過多症之組合物及方法
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
CN114026088A (zh) 2022-02-08
SG11202108607QA (en) 2021-09-29
JP2022520083A (ja) 2022-03-28
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
JP2025032217A (ja) 2025-03-11
FR3092581A1 (fr) 2020-08-14
MX2021009423A (es) 2021-11-17
IL285427A (en) 2021-09-30
KR20210148110A (ko) 2021-12-07
EP3927704A4 (en) 2022-12-28
US20220332706A1 (en) 2022-10-20
EP3927704A1 (en) 2021-12-29
EA202192237A1 (ru) 2021-12-14

Similar Documents

Publication Publication Date Title
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
JP2025032217A (ja) Ｊａｋ２阻害剤の結晶形態
CN113840604B (zh) Jak2抑制剂的结晶形式
US11053214B2 (en) Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
TWI816791B (zh) 一種稠環嘧啶類化合物的鹽、晶型及其製備方法和應用
WO2020244349A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
TW202033517A (zh) Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物
JP2023536892A (ja) Ｊａｋ阻害剤化合物及びその使用
CA3239187A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
TWI865447B (zh) 化合物的晶型
US20250101017A1 (en) Salt crystal form and free base crystal form of kinase inhibitor
WO2019056003A1 (en) CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
JP2021527120A (ja) 塩形態
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
CN120457133A (zh) Jak1/tyk2抑制剂的多晶型物及其用途
HK40079890A (en) Compositions and methods related to picolinylpiperidine 5-ht1f agonists
WO2019042383A1 (zh) Galunisertib的晶型及其制备方法和用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted